Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

Blood. 2015 Dec 10;126(24):2646-9. doi: 10.1182/blood-2015-09-670802. Epub 2015 Oct 7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • B-Lymphocytes / drug effects
  • Capillary Leak Syndrome / chemically induced
  • Clinical Trials, Phase I as Topic / statistics & numerical data
  • Clinical Trials, Phase II as Topic / statistics & numerical data
  • Cytokines / metabolism*
  • Edema / chemically induced
  • Humans
  • Hypotension / chemically induced
  • Hypoxia / chemically induced
  • Infusions, Intravenous
  • Interleukin-6 / metabolism
  • Interleukin-8 / metabolism
  • Killer Cells, Natural / immunology
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / physiopathology
  • Lymphocyte Depletion
  • Multicenter Studies as Topic / statistics & numerical data
  • Syndrome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • CXCL8 protein, human
  • Cytokines
  • IL6 protein, human
  • Interleukin-6
  • Interleukin-8
  • obinutuzumab